ICM
NKTR icon

ISZO Capital Management’s Nektar Therapeutics NKTR Stock Holding History

ISZO Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$2.48M Buy
+7,057
New +$1.59M 4.32% 10

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ISZO Capital Management's NKTR Position: Q1 2017 in Review

ISZO Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2017: 7,057 shares worth $2.48M. The stake represents 4.32% of the portfolio and ranks #10 among its holdings.

201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • ISZO Capital Management held 7,057 shares of Nektar Therapeutics worth $2.48M as of Q1 2017.
  • Nektar Therapeutics was a new ISZO Capital Management position in Q1 2017.
  • Nektar Therapeutics made up 4.32% of ISZO Capital Management's portfolio in Q1 2017, its #10 holding.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on ISZO Capital Management's 13F filing for Q1 2017, filed 15 May 2017.